Videos

In the phase 3 SPOTLIGHT trial, PET imaging with 18F-rhPSMA-7.3 frequently led to post-scan disease upstaging compared with baseline conventional imaging in men with prostate cancer recurrence.

“Focal therapy represents a middle ground between active surveillance and more radical options,” says Rafael Sanchez-Salas, MD.

“We really try to be careful about testing, especially when it's a potential burden of costs on the patient. What we really look at is where it's going to have an impact,” says Stephen J. Savage, MD.

“SWIU has just, in my humble opinion, gained incredible traction in the last few years, and it's a really great organization,” says Kara L. Watts, MD.

The AUA partnered with ASTRO on the guideline and it was endorsed by the SUO.

A regimen combining the PARP inhibitor and the androgen receptor pathway inhibitor plus prednisone showed promise in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations who had progressed on prior treatment with an androgen receptor–targeted therapy.

“I think this represents an entirely new way of treating bladder cancer,” says William C. Huang, MD.

No grade 3 TEAEs were reported in more than 1 patient at a time, and investigators deemed these grade 3 TEAEs to be unrelated to darolutamide treatment.

“I had long thought that vitamin D deficiency could be a risk factor for prostate cancer,” says Adam B. Murphy, MD, MBA, MSCI.

Tanya Dorff, MD, discusses findings from a phase 1 clinical trial that explored the use of chimeric antigen receptor (CAR) T-cell therapy in patients with prostate cancer.

Key opinion leaders review the CONDOR clinical trial studying PSMA PET scans for prostate cancer imaging.

Michael Gorin, MD, presents a clinical example of a 60-year-old patient with recurrent prostate cancer.

"Anatomic radical prostatectomy really transformed radical prostatectomy from a very morbid operation with high risk, performed rarely, to one that became a commonly utilized treatment for prostate cancer," says Christopher L. Amling, MD, FACS.

Zeyad Schwen, MD, highlights 5 studies in prostate cancer being presented at the 2022 American Urological Association Annual Meeting.

Nima Almassi, MD, highlights 5 studies in bladder cancer being presented at the 2022 American Urological Association Annual Meeting.

Amy Krambeck, MD, highlights 6 studies in BPH and urinary stones being presented at the 2022 American Urological Association Annual Meeting.

“For the first time, we have 20-year follow-up data after the penile prosthesis,” says Mohit Khera, MD, MBA, MPH.

Amy M. Pearlman, MD, highlights 6 studies in sexual dysfunction and infertility being presented at the 2022 American Urological Association Annual Meeting.

A panel of experts review whether bone scans still have a place in prostate cancer imaging.

Steven Finkelstein, MD, DABR, FACRO, presents a high-risk prostate cancer patient profile for a 74-year-old man with a history of chronic prostatitis.

"Micro TESE is associated with higher sperm retrieval rates compared with conventional testicular sperm extraction, so this approach has really become the gold standard for sperm extraction in patients with non-obstructive azoospermia," says Denise Asafu-Adjei, MD, MPH.

“Mitomycin gel, or Jelmyto, is the first agent that gives us a chance to be able to treat these low-grade upper tract cancers of the ureter and the kidney and prevent their recurrence,” says Munver.

"This non face-to-face care coordination done 'incident to' to the provider...is reimbursable through chronic care management codes," says Shirley Lee, CRNP-FNP, MPH.

“leva can help women successfully do pelvic floor muscle training and experience symptom resolution,” says Samantha Pulliam, MD.

“We really need to listen to what people care about and speak to that,” says Shirley Lee, CRNP-FNP, MPH.

Lawrence Saperstein, MD, reviews the patient profile of a 65-year-old man with high-risk prostate cancer.

A look at how PSMA PET imaging fits into the monitoring of a patient with prostate cancer.

“Any kind of complicated cancer surgery requires an experienced team from beginning to end,” says David Lee, MD.

“We had fantastic completion of the study, and we were very pleased with the results,” says Samantha Pulliam, MD.

"β3 agonists really provided a new drug class of medications for patients with overactive bladder. Previously, there were no alternatives," says Ekene Enemchukwu, MD, MPH.